RedHill Biopharma Ltd.

RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the U.S. development and commercialization of drugs for gastrointestinal (GI) diseases, infectious diseases, and oncology. The company's main goal is to become a leading specialty biopharmaceutical company, with a current focus on advancing its pipeline of clinical-stage therapeutic candidates. RedHill Biopharma also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin), in the U.S. through a partnership with Cumberland. The company continues to explore strategic plans for other potential products and activities. RedHill Biopharma Ltd. was incorporated on August 3, 2009, as a private company limited by shares under the laws of the State of Israel. Its principal executive offices are located at 21 Ha'arba'a Street, Tel-Aviv, Israel. The company completed its initial public offering in Israel in February 2011, issuing 14,302,300 Ordinary Shares and 7,151,150 tradable Series 1 Warrants for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company listed ADSs on Nasdaq, which were subsequently listed on the Nasdaq Global Market on July 20, 2018. On February 13, 2020, its Ordinary Shares were voluntarily delisted from the Tel-Aviv Stock Exchange. On November 15, 2023, the ADSs were transferred from the Nasdaq Global Market to Nasdaq, where they are currently traded under the symbol "RDHL." The company's capital expenditures for the years ended December 31, 2025, 2024, and 2023, were approximately $4,500, $8,700, and $9,500, respectively, primarily involving basic equipment and leasehold improvements.